Table 5 Outcome
| Â | Volume group | Dobutamine group |
|---|---|---|
Cardiovascular complications | Â | Â |
   Acute heart failure | 2 | 0 |
   Pulmonary edema | 8 | 3 |
   Acute myocardial infarction | 0 | 1 |
   Cardiac arrhythmia | 2 | 0 |
   Mesenteric infarction | 1 | 0 |
   Number of patients with cardiovascular complications (%) | 13 (52%) | 4 (16%)* |
Infectious complications | Â | Â |
   Pneumonia | 5 | 7 |
   Peritonitis | 3 | 3 |
   Urinary tract infection | 1 | 2 |
   Fistula | 1 | 2 |
   Severe sepsis/septic shock | 7 | 4 |
   Number of patients with infectious complications (%) | 7 (28%) | 12 (48%) |
Other complications | Â | Â |
   Postoperative bleeding | 1 | 0 |
   Upper gastrointestinal bleeding | 0 | 1 |
   Acute renal failure | 3 | 1 |
   Acute respiratory failure | 5 | 2 |
   Number of patients with other complications (%) | 9 (36%) | 4 (16%) |
Total number of complications | 39 | 26 |
   Number of patients with complications (%) | 17(68%) | 14(56%) |
   Number of achievers with complications (%) | 14 (74%) | 14 (58%) |
   C-reactive protein on day 1 (mg/dl) | 18 (11-23) | 13 (10-18) |
   Median duration of intensive care unit stay (days) | 3 (2.0-6.0) | 3(3.0-8.5) |
   Median duration of hospital stay (days) | 14 (8.5-8.5) | 20 (14.5-32) |
Mortality rate | Â | Â |
   28 days | 5 (20%) | 2 (8%) |
   60 days | 7 (28%) | 2 (8%) |